Is Teva (TEVA 2.05%) genuinely concerned about Biogen's (BIIB 2.04%) BG-12's safety, or is it more concerned about the oral MS drug's impact to its own Copaxone sales? Motley Fool health-care analyst David Williamson dives into the surprise plea to the FDA and what it means for investors.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.